ETFs Arrowhead Pharmaceuticals, Inc.

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
70.09 ^USD	-1.03%		+14.08%	+272.82%

12-11	RBC Raises Price Target on Arrowhead Pharmaceuticals to $80 From $52, Keeps Outperform, Speculative Risk	MT
12-08	Arrowhead Starts Phase 1/2a Study of ARO-MAPT to Treat Tauopathies, Including Alzheimer's Disease	MT

ETFs positioned on Arrowhead Pharmaceuticals, Inc.

Name	Weight	AuM	Varia. Jan 1.	Investor
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD	0.05%	7 M€	+14.65%	-
ADAPTIVE RH HEDGED MULTI-ASSET INCOME ETF - USD	0.01%	31 M€	+3.25%	-
VANGUARD US TOTAL MARKET SHARES INDEX ETF	0.01%	293,477 M€	+8.96%	-

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

711

Sector

Biotechnology & Medical Research

Calendar

02-09 - Q1 2026 Earnings Release (Projected)

More about the company